Nycomed Amersham Imaging
This article was originally published in The Gray Sheet
Executive Summary
Firm commences Phase I clinical trial of lung imaging agent NC100182 to document safety following investigational new drug approval. Based on "spin signal" technology, the firm "is hopeful that potential applications will include use in patients with asthma, cystic fibrosis, chronic obstructive lung disease such as emphysema and patients undergoing transplantation and lung volume reduction surgery." The technology was derived in part through the acquisition of Magnetic Imaging Technologies last year. The Phase I trial is expected to close in the fall and a Phase II trial examining the agent could begin in early 2001
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.